ERBB2 and invasive ductal breast carcinoma: The two other subjects, subject 17 with ER+ (ER+ /PR-/HER2-) invasive ductal carcinoma and Subject 29 with HER2 + (ER+/PR+/HER2+) invasive ductal carcinoma, showed no significant differences in HER3 expression from baseline.